{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T07:01:58Z","timestamp":1780124518876,"version":"3.54.0"},"reference-count":18,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chemotherapy-induced adverse drug reactions (ADRs) pose substantial clinical and economic challenges for cancer patients, particularly in resource-limited settings. This study evaluated the incidence, severity, management, and cost burden of chemotherapy-related ADRs in a tertiary care hospital.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective observational study was conducted among 415 patients receiving chemotherapy between September 2024 and April 2025. Data on ADR profiles, severity, causality, quality of life, medication adherence, and treatment-related costs were systematically collected and analyzed using appropriate statistical methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean age of the study population was 50.42\u2009\u00b1\u200919.64 years, with hypertension and diabetes being the most common comorbidities (21.0%). Lung cancer (16.1%), lymphoma (15.9%), and prostate cancer (14.9%) were the most frequently reported malignancies. Anemia (33.7%), nausea and vomiting (29.2%), and alopecia (23.9%) were the most common ADRs. Most reactions were moderate in severity (55.9%), followed by mild (29.6%) and severe (14.5%). Nearly half of the patients incurred ADR management costs exceeding \u20b910,000. ADR severity was significantly associated with higher economic burden (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and poorer quality of life (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Medication adherence declined with increasing age, with no patients aged \u226580 years demonstrating high adherence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Chemotherapy-induced ADRs represent a significant clinical and economic burden. Strengthened pharmacovigilance, individualized treatment strategies, and cost-effective interventions are essential to improve patient safety and optimize oncology care outcomes\n                      <jats:bold>.<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261445811","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:15:16Z","timestamp":1777554916000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Burden and clinical impact of chemotherapy-induced adverse drug reactions: A prospective observational study"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8389-5836","authenticated-orcid":false,"given":"Ajith","family":"JS","sequence":"first","affiliation":[{"name":"METs Institute of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gangadhar B","family":"Magar","sequence":"additional","affiliation":[{"name":"METs Institute of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6959-2994","authenticated-orcid":false,"given":"Khayati","family":"Moudgil","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, School of Pharmacy, JSS Academy of Higher Education and Research","place":["Mauritius"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devyani L","family":"Patil","sequence":"additional","affiliation":[{"name":"METs Institute of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Triveni P","family":"Tajve","sequence":"additional","affiliation":[{"name":"METs Institute of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samruddhi R","family":"Waghchaure","sequence":"additional","affiliation":[{"name":"METs Institute of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"e_1_3_2_2_2","unstructured":"World Health Organization. Cancer. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer (accessed 8 March 2025)."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_352_20"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.4103\/0971-5851.177015"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.JCRT_1015_19"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1590\/S1516-31802006000200003"},{"key":"e_1_3_2_8_2","first-page":"625","article-title":"Serious adverse effects occurring after chemotherapy: a cancer registry-based incidence survey","volume":"86","author":"Ingrand I","year":"2020","unstructured":"Ingrand I, Defossez G, Lafay-Chebassier Cet al.Serious adverse effects occurring after chemotherapy: a cancer registry-based incidence survey. Eur J Cancer 2020; 86: 625\u2013627. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7098860\/.","journal-title":"Eur J Cancer"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06855-9"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.5530\/jyp.2017.9.113"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.4103\/sajc.sajc_218_18"},{"key":"e_1_3_2_12_2","first-page":"242","article-title":"Clinical study on possibility of antineoplastic agents induced adverse drug reactions in male and female cancer patients","volume":"7","author":"Thomas J","year":"2018","unstructured":"Thomas J, Cherian JS, Vijay MC. Clinical study on possibility of antineoplastic agents induced adverse drug reactions in male and female cancer patients. J Med Pharm Allied Sci 2018; 7:242-6: 242.","journal-title":"J Med Pharm Allied Sci"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.21037\/jhmhp-20-68"},{"key":"e_1_3_2_14_2","article-title":"Evaluation of chemotherapy-induced adverse drug reactions in cancer patients","volume":"14","author":"Koliyakodu PS","year":"2021","unstructured":"Koliyakodu PS, Sudhakar R, Kurian MM, et al. Evaluation of chemotherapy-induced adverse drug reactions in cancer patients. Indian J Pharm Pract 2021; 14: \u20138.","journal-title":"Indian J Pharm Pract"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_3_2_16_2","first-page":"2229","article-title":"Preventability and severity assessment in reporting adverse drug reactions","volume":"49","author":"Hartwig SC","year":"1992","unstructured":"Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992; 49: 2229\u20132232.","journal-title":"Am J Hosp Pharm"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32981"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(99)00130-9"},{"key":"e_1_3_2_19_2","first-page":"42","article-title":"Assessment of prescribing pattern of chemotherapy drugs and monitoring of adverse drug reaction in cancer patients","volume":"8","author":"Aghamohammadi H","year":"2019","unstructured":"Aghamohammadi H, Shrestha S, Kavousi S, et al. Assessment of prescribing pattern of chemotherapy drugs and monitoring of adverse drug reaction in cancer patients. Int J Pharm Sci Invent 2019; 8: 42\u201351.","journal-title":"Int J Pharm Sci Invent"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261445811","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261445811","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261445811","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:14:14Z","timestamp":1780121654000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261445811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":18,"alternative-id":["10.1177\/10781552261445811"],"URL":"https:\/\/doi.org\/10.1177\/10781552261445811","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"article-number":"10781552261445811"}}